Final overall survival (OS) in PROpel: Abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC)
Journal of clinical oncology, 2023, Vol.41 (6_suppl), p.LBA16-LBA16 [Peer Reviewed Journal]ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2023.41.6_suppl.LBA16
Full text available
|
||||
 |
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY |  |
(84-028) 37 755 057 | Feedback |
| 19 Nguyen Huu Tho St. Dist.7, HCM |  |
thuvien@tdtu.edu.vn | ||